Core Insights - The company reported a revenue of RMB 6.635 billion for 2024, representing a year-on-year growth of 0.4% [1] - The net profit attributable to shareholders was RMB 733 million, with a year-on-year increase of 2.6% [1] - Adjusted net profit reached RMB 1.018 billion, showing a significant year-on-year growth of 41.6% [1] Revenue Breakdown - Revenue from innovative drug business was RMB 4.928 billion, accounting for 74.3% of total revenue, with a year-on-year growth of 3.6% [1] - Neuroscience revenue was RMB 2.174 billion, representing 32.8% of total revenue, with a year-on-year increase of 10.4% [1] - Autoimmune revenue was RMB 1.811 billion, making up 27.3% of total revenue, with a year-on-year growth of 28.0% [1] - Oncology revenue was RMB 1.298 billion, accounting for 19.6% of total revenue, with a year-on-year decline of 17.6% [1] - Other fields generated RMB 1.352 billion, representing 20.3% of total revenue, with a year-on-year decline of 18.0% [1] Product Development and Collaborations - The company has eight innovative drugs in the commercialization stage, with two new products recently approved in China [2] - The newly approved products include Enlituzumab for mCRC and Xianbixin sublingual tablets for AIS [2] - A collaboration agreement was signed with Shenzhen Tajiri Biopharmaceutical Co., Ltd. for exclusive commercialization rights of NSCLC drug TGRX-326 in mainland China [2] Strategic Partnerships - A licensing option agreement was established with AbbVie Inc. for the investigational drug SIM0500, retaining rights in Greater China [4] - Collaboration with Guangzhou Fermi Technology Co., Ltd. for a pain relief candidate FZ002-037, securing exclusive rights in Greater China [4] - Partnership with Jinyu Boworunze Biotechnology Co., Ltd. for the commercialization of Tocilizumab injection in Greater China [4] Production Capacity and Innovation Initiatives - The company is enhancing production capacity to align with its Innovation 2.0 strategy, with a new production base completed in 12 months [4] - A new production license for Ledeqi Bevacizumab injection was approved in April 2024 [4] - The company plans to invest RMB 2 billion over five years in the "Seeking Innovation" program, focusing on ten scientific challenges in neuroscience and oncology [5] Research Directions - The ten research directions include reversing high mortality and disability rates in stroke treatment, precision treatment for neurodegenerative diseases, and enhancing cancer treatment efficacy [5] - Other areas of focus include RNA interference/mRNA technology applications, next-generation cell therapy, gene editing, and AI applications in drug discovery and clinical efficacy prediction [5]
先声药业去年创新药收入49.28亿元，计划5年投入20亿元聚焦神经与肿瘤领域